LY86-AS1 predicts poor prognosis and inhibits progression in non-small cell lung cancer by targeting the miR-132-3p/RB1CC1 axis

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Despite significant advances in surgery, radiotherapy, chemotherapy, and targeted and immunotherapy, the overall five-year survival of NSCLC patients is still dismally low. The objective of this investigation was to evaluate the potential of LY86-AS1 as a prognostic biomarker in NSCLC and to elucidate its associated molecular regulatory network. Expression levels of LY86-AS1, miR-132-3p, and RB1CC1 were detected in NSCLC tissues and cell lines using RT-qPCR. The correlation of LY86-AS1 expression with clinical pathological characteristics was evaluated using the Kaplan-Meier curve and multivariate Cox regression analysis. CCK-8 and Transwell assays were then performed to test the effects of LY86-AS1, miR-132-3p, and RB1CC1 on the proliferation, migration, and invasion of NCI-H1299 and A549 cells. LY86-AS1 was significantly underexpressed in NSCLC. Low levels of LY86-AS1 were strongly associated with a poor prognosis and were independent prognostic factors. Overexpression of LY86-AS1 significantly inhibited the proliferation, migration, and invasion of NSCLC cells. Mechanistically, overexpression of miR-132-3p reversed the inhibitory effect of LY86-AS1 on NSCLC cells, while the overexpression of RB1CC1 abolished the oncogenic effect of miR-132-3p. LY86-AS1 upregulates RB1CC1 expression by sponging miR-132-3p, thereby inhibiting the malignant progression of NSCLC and is a potential prognostic biomarker and therapeutic target for NSCLC.